Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.
about
Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients.Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric EpendymomaPopulation pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.Population pharmacokinetics of lenalidomide in multiple myeloma patients.Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics.Exogenous ghrelin administration increases alcohol self-administration and modulates brain functional activity in heavy-drinking alcohol-dependent individuals.Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment.Increased cortisol metabolism in women with pregnancy-related hypertension.
P2860
Q36506472-7DB05FB7-D46B-43E8-864D-8363D88B65A1Q36805228-9DB56FB6-FA69-4631-A7EA-B96BDE709B0EQ37030693-D20A2990-8125-4CA5-92D5-7F5E7E8C7E9CQ39048427-80D626F6-57C2-4CE9-BE8B-7D59C4D2A560Q39357557-D143C56E-448A-4028-9529-C63DA3762BC9Q39675766-B3F3D0AC-44E0-4916-8C06-E54F49E2BB2CQ45865167-987452F9-4397-4781-8E6C-8BE177589842Q47219276-C8970629-AF9A-4957-B3DC-DFF7A88F4A2FQ47603883-4536747E-F424-4933-9D58-FBF5EF404D47Q47689257-CF5A1C02-EBF8-4198-A338-49B86E5A351FQ52317955-306D958C-C70F-4F2A-86B2-1521F393F3DFQ55340062-0CFEB245-B349-4235-8485-9ADFC844582A
P2860
Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Incorporation of concentration ...... tion pharmacokinetic analyses.
@ast
Incorporation of concentration ...... tion pharmacokinetic analyses.
@en
type
label
Incorporation of concentration ...... tion pharmacokinetic analyses.
@ast
Incorporation of concentration ...... tion pharmacokinetic analyses.
@en
prefLabel
Incorporation of concentration ...... tion pharmacokinetic analyses.
@ast
Incorporation of concentration ...... tion pharmacokinetic analyses.
@en
P2093
P2860
P356
P1476
Incorporation of concentration ...... tion pharmacokinetic analyses.
@en
P2093
Alwin D R Huitema
Bas Thijssen
Hilde Rosing
Jan H M Schellens
Jos H Beijnen
Robert S Jansen
Ron J Keizer
P2860
P304
P356
10.1002/PRP2.131
P577
2015-03-25T00:00:00Z